TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience reported encouraging results from the HeROPA study, highlighting significant progress in their pharmaceutical and dietary supplement sectors. The company secured NOK 30 million in financing, launched a new skincare product, and reduced operational costs significantly. Despite challenges in the dietary supplement business due to a recall, revenue and margins improved, and the company plans to expand its skincare product internationally. The positive development in Arctic Algae and the strategic focus on expanding B2C business and cost management are expected to strengthen their market position.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. The company is developing HRO350, a new oral drug candidate for the treatment of mild-to-moderate psoriasis. Their dietary supplements are sold globally under the ROMEGA® brand.
Average Trading Volume: 76,266
Current Market Cap: NOK110.4M
For detailed information about 9TD stock, go to TipRanks’ Stock Analysis page.